Tuberculosis/COVID-19 co-infection detected in a single sputum sample using a rapid molecular test
Abstract Tuberculosis (TB) and COVID-19 affect the lungs and are transmitted mainly by aerosols or particles of saliva from infected persons. Clinical similarities between diseases can affect correct diagnosis. Individuals belonging to the population deprived of liberty (PDL) are at increased risk of contagion due to precarious sanitary conditions and overcrowded environments. A variety of specimens may be suitable for the diagnosis of COVID-19, using molecular diagnostic techniques; however, there is little data on the analysis of sputum samples with the Xpert Xpress SARS-CoV-2® for the diagnosis of COVID-19, especially in this population group. The present study reports a case of TB and COVID-19 co-infection detected in sputum from an individual belonging to the PDL. For the detection, it used the GeneXpert platform (Cepheid, USA). Mycobacterium tuberculosis complex (MTC) was detected using the Xpert MTB/RIF Ultra® cartridge and SARS-CoV-2 was detected using the Xpert Xpress SARS-CoV-2® cartridge. The genes IS6110 and IS1081 were detected within 80 min indicating the presence of MTC, with no mutations related to resistance to rifampicin. The SARS-CoV-2 E and N2 genes were detected within 45 min. The result was confirmed by RT-qPCR with detection of E, N, and RdRP/S genes in the sputum and nasopharyngeal (NP) specimens. Rapid diagnoses that allow the identification and differentiation of such diseases are important for adequate epidemiological surveillance, isolation of infected individuals, and interruption of the transmission chain. Using the GeneXpert platform, specimens can be tested as soon as they are received, without the need for prior preparation. The US Food and Drug Administration has issued emergency authorization for the use of the Cepheid Xpert Xpress SARS-CoV-2 for the rapid detection of SARS-CoV-2 using specimens from a NP or nasal wash/aspirate. The case presented here gains an innovation with the use of the sputum to COVID-19 diagnosis..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Brazilian journal of microbiology - 53(2022), 2 vom: 02. Feb., Seite 633-639 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guirelli, Akemi Oshiro [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
© The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia 2022 |
|---|
| doi: |
10.1007/s42770-021-00677-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC207880584X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC207880584X | ||
| 003 | DE-627 | ||
| 005 | 20230511070509.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s42770-021-00677-y |2 doi | |
| 035 | |a (DE-627)OLC207880584X | ||
| 035 | |a (DE-He213)s42770-021-00677-y-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a 12 |2 ssgn | ||
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 100 | 1 | |a Guirelli, Akemi Oshiro |e verfasserin |0 (orcid)0000-0003-4518-6518 |4 aut | |
| 245 | 1 | 0 | |a Tuberculosis/COVID-19 co-infection detected in a single sputum sample using a rapid molecular test |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia 2022 | ||
| 520 | |a Abstract Tuberculosis (TB) and COVID-19 affect the lungs and are transmitted mainly by aerosols or particles of saliva from infected persons. Clinical similarities between diseases can affect correct diagnosis. Individuals belonging to the population deprived of liberty (PDL) are at increased risk of contagion due to precarious sanitary conditions and overcrowded environments. A variety of specimens may be suitable for the diagnosis of COVID-19, using molecular diagnostic techniques; however, there is little data on the analysis of sputum samples with the Xpert Xpress SARS-CoV-2® for the diagnosis of COVID-19, especially in this population group. The present study reports a case of TB and COVID-19 co-infection detected in sputum from an individual belonging to the PDL. For the detection, it used the GeneXpert platform (Cepheid, USA). Mycobacterium tuberculosis complex (MTC) was detected using the Xpert MTB/RIF Ultra® cartridge and SARS-CoV-2 was detected using the Xpert Xpress SARS-CoV-2® cartridge. The genes IS6110 and IS1081 were detected within 80 min indicating the presence of MTC, with no mutations related to resistance to rifampicin. The SARS-CoV-2 E and N2 genes were detected within 45 min. The result was confirmed by RT-qPCR with detection of E, N, and RdRP/S genes in the sputum and nasopharyngeal (NP) specimens. Rapid diagnoses that allow the identification and differentiation of such diseases are important for adequate epidemiological surveillance, isolation of infected individuals, and interruption of the transmission chain. Using the GeneXpert platform, specimens can be tested as soon as they are received, without the need for prior preparation. The US Food and Drug Administration has issued emergency authorization for the use of the Cepheid Xpert Xpress SARS-CoV-2 for the rapid detection of SARS-CoV-2 using specimens from a NP or nasal wash/aspirate. The case presented here gains an innovation with the use of the sputum to COVID-19 diagnosis. | ||
| 650 | 4 | |a Co-infection | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Tuberculosis, population deprived of liberty, vulnerable population | |
| 700 | 1 | |a Bispo, Thayná Rosa |0 (orcid)0000-0003-4707-1618 |4 aut | |
| 700 | 1 | |a Colpas, Daniela Rodrigues |0 (orcid)0000-0002-5901-2095 |4 aut | |
| 700 | 1 | |a de Campos, Ivana Barros |0 (orcid)0000-0003-0334-0572 |4 aut | |
| 700 | 1 | |a Chimara, Erica |0 (orcid)0000-0001-9574-8449 |4 aut | |
| 700 | 1 | |a Cergole-Novella, Maria Cecília |0 (orcid)0000-0001-9671-825X |4 aut | |
| 700 | 1 | |a Rodart, Itatiana Ferreira |0 (orcid)0000-0001-8370-9303 |4 aut | |
| 700 | 1 | |a dos Santos Candido, Valéria |0 (orcid)0000-0002-1922-4771 |4 aut | |
| 700 | 1 | |a Segura-Ramírez, Paula Jimena |0 (orcid)0000-0003-0059-2600 |4 aut | |
| 700 | 1 | |a dos Santos Menezes Gaiotto Daros, Vilma |0 (orcid)0000-0001-8359-0111 |4 aut | |
| 700 | 1 | |a dos Santos Carmo, Andreia Moreira |0 (orcid)0000-0002-0602-4623 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brazilian journal of microbiology |d Springer International Publishing, 2000 |g 53(2022), 2 vom: 02. Feb., Seite 633-639 |w (DE-627)326978461 |w (DE-600)2042078-X |w (DE-576)515652016 |x 1517-8382 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2022 |g number:2 |g day:02 |g month:02 |g pages:633-639 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s42770-021-00677-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2022 |e 2 |b 02 |c 02 |h 633-639 | ||